Topical Ruxolitinib Evaluation in Chronic Hand Eczema

Launched by INCYTE CORPORATION · Jun 7, 2023

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of CHE for at least 6 months prior to screening. Diagnosis of chromic hand eczema (CHE) as defined by hand eczema (HE) lasting \> 3 months or ≥ 2 flares within the previous 12 months.
• • Screening and baseline IGA-CHE 3 or 4.
• • Baseline CHE-related Itch NRS ≥ 4.
• • Have been treated with at least 1 prescription CHE therapy or if such therapy was not advisable or contraindicated.
• • Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.
• Exclusion Criteria:
• • Known triggers for CHE (allergic or irritant, such as those identified by previous patch tests) cannot be avoided during the course of this study.
• • Any serious illness or medical, physical, or psychiatric condition(s).
• • Laboratory values outside of the protocol-defined criteria.
• • Use of protocol-defined treatments within the indicated washout period before baseline.
• • Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within 4 weeks before baseline.
• • Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.
• • Other protocol-defined Inclusion/Exclusion Criteria may apply.

Trial Officials